EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity

Chongyu Wang, Xiaojie Ji, Xinrui Li, Yu Li

Frontiers in Pharmacology · 17.11.2026 · 17

DOI: 10.3389/fphar.2026.2006020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.11.2026. Verfasst von Chongyu Wang und 3 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis offers a route to hepatocellular carcinoma (HCC) vulnerability whose immunological consequences depend on the affected cell and its death or stress state. This structured evidence-mapped critical review integrates mechanistic causality, model context, traditional Chinese medicine (TCM) provenance, and cellular attribution across tumor, immune, and hepatic compartments. Seven full-text-verified Broad-TCM HCC studies comprised two M1 and five M2 studies: one-sided evidence and same-system ferroptosis-related and immune effects, respectively. This distribution identifies matched causal mediation as the next experimental priority. Direct-HCC and non-HCC mechanistic studies explain how tumor-cell ferroptosis can engage antitumor immunity while lipid-peroxidative injury to effector lymphocytes, dendritic cells, or nonmalignant hepatocytes can impair treatment. We propose a cell-selective immunoferroptosis framework that couples tumor-cell ferroptotic death to preservation of beneficial immune function and nonmalignant liver, with suppressive myeloid populations targeted according to their functional response. Development proceeds from cell-resolved causal rescue and immune-dependency testing to comparative assessment of tumor, immune, and hepatic effects at effective exposures. Clinical studies then connect deliverable exposure, biomarker concordance, efficacy, and hepatic safety within defined treatment and etiological settings. This evidence-based sequence provides a pharmacological research agenda for translating TCM-related ferroptosis–immune observations into testable therapeutic strategies.

Zitieren

APA

Wang, C., Ji, X., Li, X., & Li, Y. (2026). The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2006020

Vancouver

Wang C, Ji X, Li X, Li Y. The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2006020

BibTeX
@article{Wang2026,
  author = {Wang, Chongyu and Ji, Xiaojie and Li, Xinrui and Li, Yu},
  title = {The ferroptosis–immunity interface in hepatocellular carcinoma: cell-specific causality, traditional Chinese medicine evidence, and therapeutic selectivity},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2006020}
}
Kostenlos starten →